shutterstock_555165064_kitreel
2 November 2022Big PharmaStaff Writer

Big pharma co buys $16.6bn for heart tech company

Johnson & Johnson (J&J) has agreed to acquire  Abiomed, a cardiovascular medical technology company, for $16.6 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More on this story

Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

More on this story

Americas
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.
Americas
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Americas
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.